CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project develops a microfluidic probe technology for personalized cancer treatment by enabling detailed molecular profiling of tumors. It focuses on improving diagnostic testing for immunotherapy, particularly for pancreatic cancer, to enhance treatment outcomes through tailored therapies.
Cancer heterogeneity has reinforced the need for personalized treatment modalities.
Pre-therapeutic diagnostic testing of heterogeneous tumors helps avoid inefficacious treatments, optimizes targeted therapy, and improves quality of life.
Within targeted therapy, immunotherapy has led to significant improvements in treatment outcomes and is swiftly being integrated in diagnostic workflows.
In this context, routine diagnostic tests currently do not exist, and treatments are further challenged by…
IBM RESEARCH GMBH
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
